Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04629781 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04629781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
May 28, 2021
Completion date
January 29, 2024
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer